CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of GrowthChief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" Segment
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic TransformationCompany reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline
